Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Growth in the market can be attributed to increase in Complicated skin and soft-tissue infection.
The global Dalbavancin market is segregated on the basis of Type as Intravenous Therapy and Oral Type. Based on Application the global Dalbavancin market is segmented in Skin Infection, Soft Tissue Infection, and Others.
The global Dalbavancin market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Dalbavancin market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Sanofi, Merck, Novartis, Gilead, GSK, Amgen, Hayao, Pfizer, Abbvie, Johnson, and others are among the major players in the global Dalbavancin market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Dalbavancin Market has been segmented as below:
Dalbavancin Market, By Type
Dalbavancin Market, By Application
Dalbavancin Market, By Region
Dalbavancin Market, By Company
The report covers:
Report Scope:
The global Dalbavancin market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Dalbavancin market share. Major industry players with significant revenue share include Sanofi, Merck, Novartis, Gilead, GSK, Amgen, Hayao, Pfizer, Abbvie, Johnson, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
Sexually Transmitted Disease Therapeutics Market
Robotic Pharmacy Prescription Dispensing Systems Market
Laboratory Information Management System Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Dalbavancin Market, By Type
5.1 Introduction
5.2 Intravenous Therapy
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Oral Type
5.3.1 Market Overview
5.3.2 Market Size and Forecast
6. Dalbavancin Market, By Application
6.1 Introduction
6.2 Skin Infection
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Soft Tissue Infection
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Others
6.4.1 Market Overview
6.4.2 Market Size and Forecast
7. Dalbavancin Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Dalbavancin, By Type
7.2.2 North America Dalbavancin, By Application
7.3 Europe
7.3.1 Europe Dalbavancin, By Type
7.3.2 Europe Dalbavancin, By Application
7.4 Asia-Pacific
7.4.1 Asia-Pacific Dalbavancin, By Type
7.4.2 Asia-Pacific Dalbavancin, By Application
7.5 Rest of the World
7.5.1 Rest of the World Dalbavancin, By Type
7.5.2 Rest of the World Dalbavancin, By Application
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Sanofi
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Merck
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Novartis
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Gilead
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 GSK
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Amgen
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Hayao
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Pfizer
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
9.9 Abbvie
9.9.1 Company Overview
9.9.2 Product/Service Landscape
9.9.3 Financial Overview
9.9.4 Recent Developments
9.10 Johnson
9.10.1 Company Overview
9.10.2 Product/Service Landscape
9.10.3 Financial Overview
9.10.4 Recent Developments
The Dalbavancin Market has been segmented as below:
Dalbavancin Market, By Type
Dalbavancin Market, By Application
Dalbavancin Market, By Region
Dalbavancin Market, By Company
SUBSCRIBE TO OUR NEWSLETTERS
